- Home
- FIVE vs RYTM Comparison
FIVE vs RYTM Comparison
Compare FIVE & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVE
- RYTM
- Stock Information
- Founded
- FIVE 2002
- RYTM 2008
- Country
- FIVE United States
- RYTM United States
- Employees
- FIVE N/A
- RYTM N/A
- Industry
- FIVE Department/Specialty Retail Stores
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- FIVE Consumer Discretionary
- RYTM Health Care
- Exchange
- FIVE Nasdaq
- RYTM Nasdaq
- Market Cap
- FIVE 7.1B
- RYTM 5.9B
- IPO Year
- FIVE 2012
- RYTM 2017
- Fundamental
- Price
- FIVE $138.89
- RYTM $86.27
- Analyst Decision
- FIVE Buy
- RYTM Strong Buy
- Analyst Count
- FIVE 18
- RYTM 13
- Target Price
- FIVE $122.88
- RYTM $89.77
- AVG Volume (30 Days)
- FIVE 1.2M
- RYTM 996.5K
- Earning Date
- FIVE 08-27-2025
- RYTM 08-05-2025
- Dividend Yield
- FIVE N/A
- RYTM N/A
- EPS Growth
- FIVE N/A
- RYTM N/A
- EPS
- FIVE 4.78
- RYTM N/A
- Revenue
- FIVE $4,035,191,000.00
- RYTM $136,863,000.00
- Revenue This Year
- FIVE $16.16
- RYTM $37.47
- Revenue Next Year
- FIVE $10.06
- RYTM $71.16
- P/E Ratio
- FIVE $29.15
- RYTM N/A
- Revenue Growth
- FIVE 10.71
- RYTM 48.88
- 52 Week Low
- FIVE $52.38
- RYTM $40.61
- 52 Week High
- FIVE $142.13
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- FIVE 64.76
- RYTM 68.06
- Support Level
- FIVE $136.51
- RYTM $86.25
- Resistance Level
- FIVE $142.13
- RYTM $92.14
- Average True Range (ATR)
- FIVE 3.86
- RYTM 3.66
- MACD
- FIVE -0.29
- RYTM -0.11
- Stochastic Oscillator
- FIVE 74.33
- RYTM 73.75
About FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.